Home  /  Resource Library  /  ASH 2018 | Pembrolizumab for R/R PMBCL patients: Results from the phase II Keynote-170 trial and updated data from the phase Ib Keynote-013

ASH 2018 | Pembrolizumab for R/R PMBCL patients: Results from the phase II Keynote-170 trial and updated data from the phase Ib Keynote-013

ASH 2018: Updated results of a study investigating pembrolizumab for treatment of relapsed primary mediastinal b-cell lymphoma.